Treatment of mucosal membranes

• US 20060204591A1
• Filed: 05/16/2006
• Published: 09/14/2006
• Est. Priority Date: 04/23/2001
• Status: Abandoned Application

• Current Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Original Assignee: NUCRYST Pharmaceuticals Corp. (The Westaim Corporation)
• Inventors: Burrell, Robert Edward, Moxham, Peter Howard, Naylor, Antony George
• Application Number:
  US11/434,958
• Publication Number:
  US 20060204591A1
• Time in Patent Office: Days
• US Class Current: 424/618
• CPC Class Codes: A01N 25/04 Dispersions, emulsions, suspoemulsions, suspension concentrates or gels foams A01N25/16
• CPC Class Codes: A01N 25/10 Macromolecular compounds
• CPC Class Codes: A01N 25/12 Powders or granules A01N25/26 takes precedence
• CPC Class Codes: A01N 59/16 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/242 Gold; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 33/38 Silver; Compounds thereof
• CPC Class Codes: A61K 33/40 Peroxides
• CPC Class Codes: A61K 47/34 Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers A61K47/10 takes precedence
• CPC Class Codes: A61K 47/38 Cellulose; Derivatives thereof
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/0075 for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
• CPC Class Codes: A61K 9/0078 for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
• CPC Class Codes: A61K 9/14 Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles microspheres A61K9/16; microcapsules A61K9/50; nanocapsules, nanoparticles of the matrix type A61K9/51
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61L 15/46 Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
• CPC Class Codes: A61L 17/145 Coating
• CPC Class Codes: A61L 2300/102 : Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
• CPC Class Codes: A61L 2300/104 : Silver, e.g. silver sulfadiazine
• CPC Class Codes: A61L 2300/404 : Biocides, antimicrobial agents, antiseptic agents
• CPC Class Codes: A61L 2300/452 : Lubricants
• CPC Class Codes: A61L 2300/606 : Coatings
• CPC Class Codes: A61L 2300/624 : Nanocapsules
• CPC Class Codes: A61L 2300/63 : Crystals
• CPC Class Codes: A61L 27/30 : Inorganic materials
• CPC Class Codes: A61L 29/10 : Inorganic materials
• CPC Class Codes: A61L 31/082 : Inorganic materials
• CPC Class Codes: A61P 1/00 : Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/02 : Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 11/00 : Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/02 : Nasal agents, e.g. decongestants
• CPC Class Codes: A61P 11/04 : for throat disorders
• CPC Class Codes: A61P 13/00 : Drugs for disorders of the urinary system
• CPC Class Codes: A61P 13/08 : of the prostate
• CPC Class Codes: A61P 15/00 : Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 17/00 : Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 : for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/04 : Antipruritics
• CPC Class Codes: A61P 17/06 : Antipsoriatics
• CPC Class Codes: A61P 17/08 : Antiseborrheics
• CPC Class Codes: A61P 17/10 : Anti-acne agents
• CPC Class Codes: A61P 19/00 : Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 : for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 27/16 : Otologicals
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 : Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 : Antibacterial agents
• CPC Class Codes: A61P 31/10 : Antimycotics
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: Y10S 424/15 : Suppositories
• CPC Class Codes: Y10T 428/31855 : Of addition polymer from unsaturated monomers

Abstract

The invention relates to the use of one or more antimicrobial metals preferably selected from silver, gold, platinum, and palladium but most preferably silver, formed with atomic disorder, and preferably in a nanocrystalline form, for reducing inflammation or infection of the mucosal membrane. The antimicrobial metal may be formulated as, or used in the form of, a nanocrystalline coating of one or more antimicrobial or noble metals, a nanocrystalline powder of one or more antimicrobial or noble metals, or a liquid or solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial or noble metals.

Claims

1-89. -89. (canceled)

90. A method of reducing inflammation or infection of a mucosal membrane, comprising:

disposing antimicrobial nanocrystalline silver in a liquid; and

contacting a problem area of the mucosal membrane with the a therapeutically effective amount of the liquid to provide a localized anti-inflammatory effect,

wherein the mucosal membrane comprises the gastrointestinal tract.

91. The method of claim 90, wherein the mucosal membrane comprises the surface of the colon.

92. The method of claim 90, wherein the mucosal membrane comprises the surface of the rectum.

93. The method of claim 90, further comprising forming the liquid into a selected from the group consisting of lozenges, gels, chewing gum, wafers, mouth washes, mouth rinses, drops, sprays, elixirs, syrups, tablets and capsules.

94. The method of claim 90, further comprising forming the liquid into a form selected from the group consisting of suppositories, toothpastes, dressings, packings, tampons, creams, gels, ointments, pastes, foams, sprays and solutions.

95. The method of claim 90, wherein the liquid is a solution, a dispersion or a suspension.

96. The method of claim 90, wherein the method treats a digestive ulcer.

97. The method of claim 96, wherein the ulcer is selected from the group consisting of esophageal ulcers, gastric ulcers and duodenal ulcers.

98. The method of claim 90, wherein the method treats esophagitis.

99. The method of claim 90, wherein the method treats gastritis.

100. The method of claim 90, wherein the method treats enteritis.

101. The method of claim 90, wherein the method treats enterogastric intestinal hemorrhage.

102. The method of claim 90, wherein the method treats colitis.

103. The method of claim 90, wherein the method treats hemorrhoids.

104. The method of claim 90, wherein the method treats inflammatory bowel disease.

105. The method of claim 104, further comprising forming the liquid into a form selected from the group consisting of suppositories, toothpastes, dressings, packings, tampons, creams, gels, ointments, pastes, foams, sprays and solutions.

106. The method of claim 104, wherein, upon forming the liquid, the liquid comprises 0.001-10% by weight of the antimicrobial nanocrystalline silver.

107. The method of claim 104, wherein, upon forming the liquid, the liquid comprises 0.01 to 5% by weight of the antimicrobial nanocrystalline silver.

108. The method of claim 104, wherein, upon forming the liquid, the liquid comprises 0.1 to 1% by weight of the antimicrobial nanocrystalline silver.

109. The method of claim 104, wherein, upon forming the liquid, the liquid comprises 1-5000 μ

g/ml of the antimicrobial nanocrystalline silver.

110. The method of claim 104, wherein, upon forming the liquid, the liquid comprises 20-3000 μ

g/ml of the antimicrobial nanocrystalline silver.

111. The method of claim 104, wherein, upon forming the liquid, the liquid comprises 40-800 μ

g/ml of the antimicrobial nanocrystalline silver.

112. The method of claim 104, wherein, upon forming the liquid, the liquid comprises 50-500 μ

g/ml of the antimicrobial nanocrystalline silver.

113. A method of reducing inflammation or infection of a mucosal membrane, comprising:

disposing antimicrobial nanocrystalline silver in a solution; and

contacting a problem area of the mucosal membrane with the a therapeutically effective amount of the solution to provide a localized anti-inflammatory effect,

wherein the mucosal membrane comprises the gastrointestinal tract, and the method treats irritable bowel syndrome.

114. The method of claim 113, wherein, upon forming the liquid, the liquid comprises 1-5000 μ

g/ml of the antimicrobial nanocrystalline silver.

115. The method of claim 113, wherein, upon forming the liquid, the liquid comprises 20-3000 μ

g/ml of the antimicrobial nanocrystalline silver.

116. The method of claim 113, wherein, upon forming the liquid, the liquid comprises 40-800 μ

g/ml of the antimicrobial nanocrystalline silver.

117. The method of claim 113, wherein, upon forming the liquid, the liquid comprises 50-500 μ

g/ml of the antimicrobial nanocrystalline silver.

118. The method of claim 113, further comprising forming the solution into a form selected from the group consisting of suppositories, toothpastes, dressings, packings, tampons, creams, gels, ointments, pastes, foams and sprays.

119. A method of reducing inflammation or infection of a mucosal membrane, comprising:

disposing antimicrobial nanocrystalline silver in a solution;

forming the solution into a form selected from the group consisting of suppositories, toothpastes, dressings, packings, tampons, creams, gels, ointments, pastes, foams and sprays; and

contacting a problem area of the mucosal membrane with the a therapeutically effective amount of the solution to provide a localized anti-inflammatory effect,

wherein the mucosal membrane comprises the gastrointestinal tract, and the method treats irritable bowel syndrome.

120. The method of claim 119, wherein, upon forming the liquid, the liquid comprises 1-5000 μ

g/ml of the antimicrobial nanocrystalline silver.